Hypoxia/reoxygenation: A dynamic regulator of lysyl oxidase-facilitated breast cancer migration

被引:68
|
作者
Postovit, Lynne-Marie [1 ]
Abbott, Daniel E. [2 ]
Payne, Stacey L. [1 ]
Wheaton, William W. [1 ]
Margaryan, Naira V. [1 ]
Sullivan, Richard [3 ]
Jansen, Matthias K. [4 ]
Csiszar, Katalin [4 ]
Hendrix, Mary J. C. [1 ]
Kirschmann, Dawn A. [1 ]
机构
[1] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Childrens Mem Res Ctr, Chicago, IL 60614 USA
[2] Northwestern Univ, Dept Surg, Feinberg Sch Med, Chicago, IL 60614 USA
[3] Queens Univ, Dept Anat & Cell Biol, Kingston, ON, Canada
[4] Univ Hawaii, John A Burns Sch Med, Cardiovasc Res Ctr, Honolulu, HI 96822 USA
关键词
motility; breast cancer; lysyl oxidase; hypoxia; reoxygenation;
D O I
10.1002/jcb.21517
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Fluctuating oxygen levels characterize the microenvironment of many cancers and tumor hypoxia is associated with increased invasion and metastatic potential concomitant with a poor prognosis. Similarly, the expression of lysyl oxidase (LOX) in breast cancer facilitates tumor cell migration and is associated with estrogen receptor negative status and reduced patient survival. Here we demonstrate that hypoxia/reoxygenation drives poorly invasive breastcancer cells toward a more aggressive phenotype by up-regulating LOX expression and catalytic activity. Specifically, hypoxia markedly increased LOX protein expression; however, catalytic activity (beta-aminopropionitrile inhibitable hydrogen peroxide production) was significantly reduced under hypoxic conditions. Moreover, poorly invasive breast cancer cells displayed a marked increase in LOX-dependent FAK/Src activation and cell migration following hypoxia/reoxygenation, but not in response to hypoxia alone. Furthermore, LOX expression is only partially dependent on hypoxia inducible factor-1 (HIF-1 alpha) in poorly invasive breast cancer cells, as hypoxia mimetics and overexpression of HIF-1 alpha could not upregulate LOX expression to the levels observed under hypoxia. Clinically, LOX expression positively correlates with tumor progression and co-localization with hypoxic regions (defined by HIF-1 alpha expression) in ductal carcinoma in situ and invasive ductal carcinoma primary tumors. However, positive correlation is lost in metastatic tumors, suggesting that LOX expression is independent of a hypoxic environment at later stages of tumor progression. This work demonstrates that both hypoxia and reoxygenation are necessary for LOX catalytic activity which facilitates breast cancer cell migration through a hydrogen peroxide-mediated mechanism; thereby illuminating a potentially novel mechanism by which poorly invasive cancer cells can obtain metastatic competency.
引用
收藏
页码:1369 / 1378
页数:10
相关论文
共 50 条
  • [31] Silencing of Lysyl Oxidase Gene Expression by RNA Interference Suppresses Metastasis of Breast Cancer
    Liu, Jian-Lun
    Wei, Wei
    Tang, Wei
    Jiang, Yi
    Yang, Hua-Wei
    Li, Jing-Tao
    Zhou, Xiao
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (07) : 3507 - 3511
  • [32] Lysyl Oxidase (LOX) Family Proteins: Key Players in Breast Cancer Occurrence and Progression
    Li, Jinsong
    Wang, Xinmeng
    Liu, Ruai
    Zi, Jiaji
    Li, Yihan
    Li, Zhengliang
    Xiong, Wei
    JOURNAL OF CANCER, 2024, 15 (16): : 5230 - 5243
  • [33] Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer
    Saatci, Ozge
    Kaymak, Aysegul
    Raza, Umar
    Ersan, Pelin G.
    Akbulut, Ozge
    Banister, Carolyn E.
    Sikirzhytski, Vitali
    Tokat, Unal Metin
    Aykut, Gamze
    Ansari, Suhail A.
    Dogan, Hayriye Tatli
    Dogan, Mehmet
    Jandaghi, Pouria
    Isik, Aynur
    Gundogdu, Fatma
    Kosemehmetoglu, Kemal
    Dizdar, Omer
    Aksoy, Sercan
    Akyol, Aytekin
    Uner, Aysegul
    Buckhaults, Phillip J.
    Riazalhosseini, Yasser
    Sahin, Ozgur
    NATURE COMMUNICATIONS, 2020, 11 (01)
  • [34] The Lysyl Oxidase Inhibitor, β-Aminopropionitrile, Diminishes the Metastatic Colonization Potential of Circulating Breast Cancer Cells
    Bondareva, Alla
    Downey, Charlene M.
    Ayres, Fabio
    Liu, Wei
    Boyd, Steven K.
    Hallgrimsson, Benedikt
    Jirik, Frank R.
    PLOS ONE, 2009, 4 (05):
  • [35] Intracellular and extracellular human lysyl oxidase-like 2 in metastatic breast cancer cells
    Xu, Li
    Rebecchi, Kathryn
    Nightengale, Roger
    Mure, Minae
    FASEB JOURNAL, 2012, 26
  • [36] Lysyl Oxidase Propeptide Sensitizes Pancreatic and Breast Cancer Cells to Doxorubicin-Induced Apoptosis
    Min, Chengyin
    Zhao, Yingshe
    Romagnoli, Mathilde
    Trackman, Philip C.
    Sonenshein, Gail E.
    Kirsch, Kathrin H.
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2010, 111 (05) : 1160 - 1168
  • [37] Overcoming chemotherapy resistance in triple negative breast cancer via targeting lysyl oxidase (LOX)
    Saatci, Ozge
    Akbulut, Ozge
    Rezaeain, Abdol-Hossein
    Banister, Carolyn
    Sikirzhytski, Vitali
    Aksoy, Sercan
    Akyol, Aytekin
    Uner, Aysegul
    Buckhaults, Phillip
    Chernov, Mikhail
    McInnes, Campbell
    Riazalhosseini, Yasser
    Sahin, Ozgur
    CANCER RESEARCH, 2021, 81 (05)
  • [38] Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy
    El-Haibi, Christelle P.
    Bell, George W.
    Zhang, Jiangwen
    Collmann, Anthony Y.
    Wood, David
    Scherber, Cally M.
    Csizmadia, Eva
    Mariani, Odette
    Zhu, Cuihua
    Campagne, Antoine
    Toner, Mehmet
    Bhatia, Sangeeta N.
    Irimia, Daniel
    Vincent-Salomon, Anne
    Karnoub, Antoine E.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (43) : 17460 - 17465
  • [39] Forkhead Box F1 promotes breast cancer cell migration by upregulating lysyl oxidase and suppressing Smad2/3 signaling
    Gisela Nilsson
    Marie Kannius-Janson
    BMC Cancer, 16
  • [40] Forkhead Box F1 promotes breast cancer cell migration by upregulating lysyl oxidase and suppressing Smad2/3 signaling
    Nilsson, Gisela
    Kannius-Janson, Marie
    BMC CANCER, 2016, 16